WNT2 and chronic myelogenous leukemia, BCR-ABL1 positive: MiRNA-199a/b-5p promoted imatinib efficacy through inhibiting the Wnt2 signaling pathway-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells26.